~~<i id='8B5821432E'><strike id='8B5821432E'><tt id='8B5821432E'><pre id='8B5821432E'></pre></tt></strike></i>~~

Home» Wikipedia» entertainment

entertainment

author：focus 2025-09-06 03:13:57 Page View：74234

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Prior authorization will have to move faster under new Biden rule
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

focus

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Why doctors need education on FDA device approval process

AdobeInherfinalpresentationforhealthpolicyclassattheUniversityofChicago,first-yearmedicalstudentRobi

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Readout Newsletter: Merck, J&J, and long Covid

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo